Version 1
: Received: 15 January 2024 / Approved: 16 January 2024 / Online: 16 January 2024 (06:36:21 CET)
How to cite:
Shirani, M.; Meshkini, A.; Hashemi, S.M.M.; Mirzaei, F.; Salami, A.; Jafari, F.; Rafiei, E.; SohrabiAsl, M.; Iranmehr, A. Deferoxamine in Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes. Preprints2024, 2024011185. https://doi.org/10.20944/preprints202401.1185.v1
Shirani, M.; Meshkini, A.; Hashemi, S.M.M.; Mirzaei, F.; Salami, A.; Jafari, F.; Rafiei, E.; SohrabiAsl, M.; Iranmehr, A. Deferoxamine in Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes. Preprints 2024, 2024011185. https://doi.org/10.20944/preprints202401.1185.v1
Shirani, M.; Meshkini, A.; Hashemi, S.M.M.; Mirzaei, F.; Salami, A.; Jafari, F.; Rafiei, E.; SohrabiAsl, M.; Iranmehr, A. Deferoxamine in Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes. Preprints2024, 2024011185. https://doi.org/10.20944/preprints202401.1185.v1
APA Style
Shirani, M., Meshkini, A., Hashemi, S.M.M., Mirzaei, F., Salami, A., Jafari, F., Rafiei, E., SohrabiAsl, M., & Iranmehr, A. (2024). Deferoxamine in Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes. Preprints. https://doi.org/10.20944/preprints202401.1185.v1
Chicago/Turabian Style
Shirani, M., Masoud SohrabiAsl and Arad Iranmehr. 2024 "Deferoxamine in Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes" Preprints. https://doi.org/10.20944/preprints202401.1185.v1
Abstract
1. Background and Objective:
Spontaneous Intracranial Hemorrhage (ICH) is a catastrophic medical condition associated with significant morbidity and mortality. As the accumulation of unbound iron following ICH contributes to secondary brain injury, deferoxamine, an approved chelation drug, has become the center of attention. At the same time, its therapeutic remains a matter of dispute. This double-blinded Randomized Controlled Trial (RCT) aims to investigate the therapeutic potential of deferoxamine in neurological and radiological aspects.
2. Methods and Materials:
The study enrolled 42 participants diagnosed with spontaneous ICH and confirmed by CT scan, randomly assigning them to either the deferoxamine treatment group or the placebo control group. While the control group received the routine treatment plus a placebo, the treatment group received routine treatment conjugated with 7.5 mg/kg of deferoxamine per hour intravenously over the first three days. The study compared hematoma and edema volume, GCS score, and mortality rates between the two groups. Our study employed rigorous randomization and blinding procedures to ensure unbiased results.
3. Results:
There was a significant (p<0.05) improvement in patients' GCS up until the fourth day, but no significant difference was noted afterward. In addition, the volume of both edema and hematoma was significantly lower in the intervention group, as well as the length of stay, intubation requirement, and mortality.
4. Discussion:
Deferoxamine administration can, at least in a short timeframe, improve neurological and radiological parameters.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
